Squarepoint’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.1M | Sell |
513,813
-338,709
| -40% | -$10.1M | 0.02% | 790 |
|
|
2025
Q4 | $25.4M | Buy |
852,522
+347,888
| +69% | +$11.4M | 0.03% | 629 |
|
|
2025
Q3 | $18.2M | Buy |
+504,634
| New | +$16.6M | 0.02% | 786 |
|
|
2025
Q2 | – | Sell |
-319,226
| Closed | -$11.9M | – | 5054 |
|
|
2025
Q1 | $12.6M | Buy |
319,226
+108,431
| +51% | +$3.65M | 0.02% | 919 |
|
|
2024
Q4 | $6.34M | Buy |
210,795
+162,082
| +333% | +$4.65M | 0.01% | 1458 |
|
|
2024
Q3 | $1.14M | Sell |
48,713
-2,998
| -6% | -$65.5K | ﹤0.01% | 2504 |
|
|
2024
Q2 | $920K | Sell |
51,711
-9,573
| -16% | -$153K | ﹤0.01% | 2613 |
|
|
2024
Q1 | $932K | Sell |
61,284
-264,540
| -81% | -$4.21M | ﹤0.01% | 2649 |
|
|
2023
Q4 | $5.57M | Buy |
325,824
+254,749
| +358% | +$2.96M | 0.01% | 1327 |
|
|
2023
Q3 | $594K | Buy |
+71,075
| New | +$991K | ﹤0.01% | 2663 |
|
|
2023
Q2 | – | Sell |
-67,179
| Closed | -$1.01M | – | 4010 |
|
|
2023
Q1 | $1.01M | Sell |
67,179
-15,954
| -19% | -$242K | ﹤0.01% | 1888 |
|
|
2022
Q4 | $983K | Sell |
83,133
-33,005
| -28% | -$240K | ﹤0.01% | 1836 |
|
|
2022
Q3 | $688K | Buy |
+116,138
| New | +$762K | ﹤0.01% | 2024 |
|
|
2022
Q1 | – | Sell |
-13,279
| Closed | -$252K | – | 3514 |
|
|
2021
Q4 | $252K | Buy |
+13,279
| New | +$345K | ﹤0.01% | 2552 |
|
|
2020
Q2 | – | Sell |
-73,590
| Closed | -$724K | – | 2513 |
|
|
2020
Q1 | $724K | Buy |
+73,590
| New | +$929K | 0.02% | 866 |
|
|
2019
Q3 | – | Sell |
-35,696
| Closed | -$309K | – | 2668 |
|
|
2019
Q2 | $309K | Buy |
35,696
+9,621
| +37% | +$72.7K | ﹤0.01% | 1922 |
|
|
2019
Q1 | $210K | Buy |
+26,075
| New | +$141K | ﹤0.01% | 1929 |
|
|
2018
Q3 | – | Sell |
-14,200
| Closed | -$187K | – | 2219 |
|
|
2018
Q2 | $187K | Sell |
14,200
-19
| -0.1% | -$261 | ﹤0.01% | 1556 |
|
|
2018
Q1 | $202K | Sell |
14,219
-3,755
| -21% | -$48K | ﹤0.01% | 1493 |
|
|
2017
Q4 | $147K | Buy |
+17,974
| New | +$157K | ﹤0.01% | 1877 |
|
|
2017
Q1 | – | Sell |
-39,605
| Closed | -$184K | – | 1895 |
|
|
2016
Q4 | $184K | Buy |
+39,605
| New | +$232K | 0.01% | 1471 |
|
|
2016
Q1 | – | Sell |
-23,500
| Closed | -$280K | – | 1442 |
|
|
2015
Q4 | $280K | Buy |
+23,500
| New | +$297K | 0.03% | 828 |
|
Other funds holding TGTX
VPM
VCM
SCM
CAM
Squarepoint's TGTX Position: Q1 2026 in Review
Squarepoint reduced its TG Therapeutics (TGTX) stake by 40% in Q1 2026, selling an estimated $10.1M and leaving 513,813 shares worth $17.1M. The position accounts for 0.02% of the portfolio, ranked #790.
Squarepoint first reported a position in TGTX in Q4 2015 and has held it in 22 quarters since. The position peaked at $25.4M in Q4 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.
- Squarepoint held 513,813 shares of TG Therapeutics worth $17.1M as of Q1 2026.
- Squarepoint sold 338,709 TG Therapeutics shares in Q1 2026, an estimated $10.1M.
- TG Therapeutics made up 0.02% of Squarepoint's portfolio in Q1 2026, its #790 holding.
- Squarepoint first reported a position in TG Therapeutics in Q4 2015 and has held it in 22 quarters since.
- Squarepoint's TG Therapeutics position peaked at $25.4M in Q4 2025.
- 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.